Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
Clinical and Molecular Hepatology · 01.04.2025 · 31 (2) · 382-393
DOI: 10.3350/cmh.2024.0987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2025. Verfasst von Donghee Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background/Aims: Multi-society experts proposed the adoption of new terminology, metabolic dysfunctionassociated steatotic liver disease (MASLD) and steatotic liver disease (SLD). We studied the current prevalence of SLD and its subcategories in the US.
Methods
Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography. SLD and its subcategories, including MASLD, metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD), were categorized according to consensus nomenclature.
Results
The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1). The prevalence of SLD and MASLD showed a statistically insignificant decrease during COVID-19, while ALD increased without significance. In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era. The proportion of advanced fibrosis and cirrhosis in individuals with ALD was two-fold higher than MASLD and MetALD, largely due to increases during the COVID-19 era.
Conclusions
While the prevalence of SLD and its subcategories remained stable, there was a significant increase in advanced fibrosis among SLD individuals during the COVID-19 era, with ALD having a proportion of advanced fibrosis and cirrhosis that was twice as high as MASLD and MetALD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
- Division of Gastroenterology and Epidemiology, University of California at San Diego, La Jolla, CA, USA.
Zitieren
APA
Kim, D., Danpanichkul, P., Wijarnpreecha, K., Cholankeril, G., Loomba, R., & Ahmed, A. (2025). Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023. Clinical and Molecular Hepatology, 31(2), 382-393. https://doi.org/10.3350/cmh.2024.0987
Vancouver
Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023. Clinical and Molecular Hepatology. 2025;31(2):382-393. doi:10.3350/cmh.2024.0987
BibTeX
@article{Kim2025,
author = {Kim, Donghee and Danpanichkul, Pojsakorn and Wijarnpreecha, Karn and Cholankeril, George and Loomba, Rohit and Ahmed, Aijaz},
title = {Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {2},
pages = {382--393},
doi = {10.3350/cmh.2024.0987}
}
EUVIMED